Margreiter R, Schmid T, Steiner E, Aigner F, Then P, Pernthaler H
I. Universitätsklinik für Chirurgie Innsbruck.
Wien Med Wochenschr. 1988 Jul 15;138(13):305-7.
Cytotoxic chemotherapy was performed in a total of 18 patients (12 men, 6 women): 5 patients with colonic carcinoma and 1 patient with unknown primary lesion received 5 x 1000 mg 5-Fluorouracil (5-FU) at 4 week interval. The 5 following patients primarily suffering from colonic carcinoma were treated with 0.5 mg/kg BW FUDR continuously at 2 week interval. 5 further patients with colonic carcinoma sequential received Mitomycin C (8 mg/m2) and 4 x 1000 mg 5-FU. 2 patients with breast cancer were treated with 500 mg/m2 Cyclophosphamide, the same amount of 5-FU and 40 mg/m2 Methotrexate every 4 weeks. Chemotherapy was well tolerated by all patients. A clinically significant response, however, was seen in only 2 patients with breast cancer. In 8 patients a liver transplantat was performed, which was followed in 3 cases by ultra-high dose Cyclosphosphamide, lethal total body irradiation and autologous bone marrow transplantation. 1 further patient received polychemotherapy. At the time of this analysis only 3 patients were still alive at 61, 30 and 26 months with only 1 perioperative death. All 3 had meanwhile developed recurrent or metastatic disease. Because of these sobering results, liver transplantation for the treatment of non-resectable liver metastases has been abandoned, and regional chemotherapy is now only applied in patients with liver metastases from breast cancer and after resection of metastases in an adjuvant setting.
共有18例患者（12例男性，6例女性）接受了细胞毒性化疗：5例结肠癌患者和1例原发灶不明的患者每隔4周接受5次1000毫克的5-氟尿嘧啶（5-FU）。接下来的5例主要患有结肠癌的患者每隔2周连续接受0.5毫克/千克体重的氟尿苷治疗。另外5例结肠癌患者依次接受丝裂霉素C（8毫克/平方米）和4次1000毫克的5-FU治疗。2例乳腺癌患者每隔4周接受500毫克/平方米的环磷酰胺、等量的5-FU和40毫克/平方米的甲氨蝶呤治疗。所有患者对化疗耐受性良好。然而，仅2例乳腺癌患者出现了具有临床意义的反应。8例患者接受了肝移植，其中3例在肝移植后接受了超高剂量环磷酰胺、致死性全身照射和自体骨髓移植。另有1例患者接受了联合化疗。在本次分析时，仅3例患者存活，分别为61个月、30个月和26个月，围手术期仅1例死亡。这3例患者均已出现复发或转移性疾病。鉴于这些令人沮丧的结果，用于治疗不可切除肝转移瘤的肝移植已被放弃，目前区域化疗仅应用于乳腺癌肝转移患者以及转移瘤切除后的辅助治疗。
